Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001102 · ClinicalTrials.gov registry record
The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 460
- Enrollment target
NCT00001102: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00001102 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 460 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001102 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 460 participants
- Enrollment target
Study Summary
The purpose of this study is to see how taking certain anti-HIV drugs affects the way the body metabolizes fat. This study will evaluate patients who are enrolled in CPCRA 058 (the FIRST \[Flexible Initial Retrovirus Suppressive Therapies\] study) by looking for changes in cholesterol levels, levels of fat in the blood, and body fat distribution. Patients in the FIRST study receive an anti-HIV drug regimen which contains a protease inhibitor (PI), a nonnucleoside reverse transcriptase inhibitor (NNRTI), or both. Anti-HIV drug therapy using PIs has become very common treatment for HIV-positive patients. Recently, however, serious side effects involving how the body uses fat are being reported in patients taking PIs. Examples of these side effects are a redistribution of body fat, high cholesterol level, and development of diabetes. However, some of these side effects have also been seen in patients who are not taking PIs. It is important to determine whether or not these side effects are directly related to PI use. In this study, patients on different drug combinations, either with or without a PI, will be compared.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Est. Completion | 2006-06 |
What the finished NCT00001102 record still lists
NCT00001102 is an observational study that tracks outcomes without assigning an intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00001102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00001102 about?
NCT00001102 is a clinical study titled "The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients". The purpose of this study is to see how taking certain anti-HIV drugs affects the way the body metabolizes fat. This study will evaluate patients who are enrolled in CPCRA 058 (the FIRST \[Flexible Initial Retrovirus Suppressive Therapies\] study) by looking for changes in cholesterol levels, levels...
What is the current status of trial NCT00001102?
This trial is currently completed. The enrollment target is 460 participants. Estimated completion is 2006-06.
Who is sponsoring clinical trial NCT00001102?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE